PARP1 and cancer: However, the applicationof SL modulators still has a long way to go, as not all cancer subtypeshave clearly defined deficiency, such as has been seen with the applicationof PARP1 and BRCA1/2 inhibitors or the 29 clinical trials currentlyinvolving ATR inhibitors.